<DOC>
	<DOCNO>NCT01623505</DOCNO>
	<brief_summary>Research Aims The aim research study : 1 . To determine follow three smoke cessation medication effective achieve cessation : - Nicotine Patch - Nicotine Patch + gum inhaler - Varenicline ( Champix ; 2 . To investigate often participant experience neuropsychiatric symptom course cessation attempt ass whether : - They occur often take one medication versus another - They occur often without psychiatric illness . Hypotheses Tested The hypothesis test include follow : 1 . The CO-confirmed continuous abstinence rate 5 week 52 week follow target quit date significantly high smoker receive long-term transdermal NRT combination NRT product receive varenicline compare receive transdermal NRT alone . 2 . Some participant experience neuropsychiatric symptom cessation attempt , varenicline group experience great incidence neuropsychiatric symptom group receive transdermal NRT alone combination NRT product . Patients psychiatric illness report high level withdrawal symptom without psychiatric illness .</brief_summary>
	<brief_title>Reducing Cardiovascular Disease Combining Smoking Cessation Pharmacotherapy Behavioural Counseling</brief_title>
	<detailed_description>Participants recruit UOHI Smoking Cessation Clinic via medium advertisement . Following baseline assessment , participant randomly assign one three group : 1 . 10-week standard regimen transdermal NRT ( NRT ) ; 2 . Long duration transdermal NRT combination NRT product ( NRT+ ) ; 3 . Varenicline ( VR ) . Participants assign `` NRT '' standard regimen group follow 10-week treatment nicotine patch alone . Participants assign `` NRT+ '' long-duration group follow regimen NRT group , limit fix decline dose strategy , limited 10-week duration ( potential maximum dosage 35mg/day maximum treatment duration 22 week ) . Participants also provide NRT product ( i.e. , gum inhaler ) . Participants assign `` VR '' group start medication day baseline assessment set target quit date time within 8 14 day period baseline . Participants receive 12-week supply varenicline possible extension 24 week . All participant receive six 15-minute counsel session nurse-counsellor specialize smoke cessation accordance nurse best-practice guideline . These session occur 1 , 3 , 5 , 8 , 10 week post target quit date . Counselling session focus practical counselling ( problem solve skill train ) social support . During treatment phase , participant complete questionnaire measure withdrawal neuropsychiatric symptom 1 , 3 , 5 , 8 , 10 week . These questionnaire also complete 22 52 week target quit date .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Participant current smoker ( â‰¥ 10 cigarette per day preceding\ six month ) ; Participant willing make quit attempt 24 week initial screening eligibility ; Participant 18 year age old ; Participant willing provide inform consent . Participant currently use use intervention medication previous 6 month ( i.e , Champix ( varenicline ) ; and/or Nicotine replacement therapy ( patch , gum , inhaler , lozenge ) ) ; Participant contraindication ( ) follow smoke cessation medication : Nicotine replacement therapy ( allergic reaction adhesive ; serious cardiac arrhythmia ( e.g. , tachycardia ) ; participant immediate postmyocardial infarction period ( i.e . incident occur within last 10 day ) ; severe worsen angina pectoris ; participant recent cerebral vascular accident ) ; Varenicline ( endstage renal disease ; use cimetidine ( participant severe renal impairment ) ; previous allergic reaction varenicline ) ; Pregnant breastfeed woman intend become pregnant next year ; Current previous ( last 3 month ) substance abuse ; Unable provide inform consent due unstable psychiatric symptom ( e.g. , active , untreated psychosis suicidality ) ; Participant unable read understand English French ; In order prevent contamination across group , one person per household may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Smoking Cessation</keyword>
	<keyword>Psychiatric Illness</keyword>
	<keyword>Pharmacotherapy</keyword>
</DOC>